Patents by Inventor Kazunobu Kira
Kazunobu Kira has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230016686Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.Type: ApplicationFiled: June 23, 2022Publication date: January 19, 2023Applicants: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
-
Patent number: 11407762Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.Type: GrantFiled: November 15, 2018Date of Patent: August 9, 2022Assignees: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
-
Publication number: 20210261566Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof.Type: ApplicationFiled: February 4, 2021Publication date: August 26, 2021Applicants: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
-
Publication number: 20210163456Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.Type: ApplicationFiled: April 8, 2019Publication date: June 3, 2021Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Gregg F. KEANEY, John WANG, Baudouin GERARD, Kenzo ARAI, Xiang LIU, Guo Zhu ZHENG, Kazunobu KIRA, Lisa A. MARCAURELLE, Marta NEVALAINEN, Ming-Hong HAO, Morgan Welzel O'SHEA, Parcharee TIVITMAHAISOON, Sudeep PRAJAPATI, Touping LUO, Nicholas C. GEARHART, Jason T. LOWE, Yoshihiko KOTAKE, Satoshi NAGAO, Regina Mikie KANADA SONOBE, Masayuki MIYANO, Norio MURAI, Andrew COOK, Shelby ELLERY, Atsushi ENDO, James PALACINO, Dominic REYNOLDS
-
Patent number: 10954249Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable and medical uses thereof.Type: GrantFiled: April 3, 2018Date of Patent: March 23, 2021Assignees: President and Fellows of Harvard College, Eisai R&D Management Co., Ltd.Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
-
Publication number: 20200361915Abstract: The present disclosure provides a novel solid state form of pladienolide pyridine compounds, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful.Type: ApplicationFiled: July 17, 2020Publication date: November 19, 2020Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Parcharee Tivitmahaisoon, Sudeep Prajapati, Nicholas C. Gearhart, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Silvia Buonamici, Lihua Yu, Eunice Sun Park, Betty Chan, Peter G. Smith, Michael P. Thomas, Ermira Pazolli, Kian Huat Lim, Atsushi Endo, Arani Chanda
-
Publication number: 20200325152Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.Type: ApplicationFiled: November 15, 2018Publication date: October 15, 2020Applicants: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
-
Patent number: 10745387Abstract: The present disclosure provides a novel solid state form of pladienolide pyridine compounds having Formula I, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful.Type: GrantFiled: November 17, 2016Date of Patent: August 18, 2020Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Parcharee Tivitmahaisoon, Sudeep Prajapati, Nicholas C. Gearhart, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Silvia Buonamici, Lihua Yu, Eunice Sun Park, Betty Chan, Peter G. Smith, Michael P. Thomas, Ermira Pazolli, Kian Huat Lim, Atsushi Endo, Arani Chanda
-
Publication number: 20200148698Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable and medical uses thereof.Type: ApplicationFiled: April 3, 2018Publication date: May 14, 2020Applicants: President and Fellows of Harvard College, Eisai R&D Management Co., LTDInventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
-
Publication number: 20190100513Abstract: The present disclosure provides a novel solid state form of pladienolide pyridine compounds, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful.Type: ApplicationFiled: November 17, 2016Publication date: April 4, 2019Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Parcharee Tivitmahaisoon, Sudeep Prajapati, Nicholas C. Gearhart, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Silvia Buonamici, Lihua Yu, Eunice Sun Park, Betty Chan, Peter G. Smith, Michael P. Thomas, Ermira Pazolli, Kian Huat Lim, Atsushi Endo, Arani Chanda
-
Patent number: 9938288Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.Type: GrantFiled: November 15, 2017Date of Patent: April 10, 2018Assignees: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
-
Patent number: 9481669Abstract: The present invention provides novel pladienolide pyridine compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.Type: GrantFiled: May 13, 2015Date of Patent: November 1, 2016Assignee: Eisai R&D Management Co., Ltd.Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Parcharee Tivitmahaisoon, Sudeep Prajapati, Nicholas C. Gearhart, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Silvia Buonamici, Lihua Yu, Eunice Sun Park, Betty Chan, Peter G. Smith, Michael P. Thomas, Ermira Pazolli, Kian Huat Lim
-
Publication number: 20150329528Abstract: The present invention provides novel pladienolide pyridine compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.Type: ApplicationFiled: May 13, 2015Publication date: November 19, 2015Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Parcharee Tivitmahaisoon, Sudeep Prajapati, Nicholas C. Gearhart, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai
-
Publication number: 20140275010Abstract: The present invention provides quaternary salts, such as those of Formula I: as well as the use thereof in methods of treatment for cancer.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Inventors: Guo Zhu Zheng, Yuan Wang, Gregg F. Keany, Kenzo Arai, Kazunobu Kira, Xiang Liu, Nick Gearhart, Baudouin Gerard
-
Patent number: 8436009Abstract: By oral administration of a compound represented by the following Formula (I): the blood level of Compound (IV): which has an excellent inhibitory action against blood coagulation factor VIIa and the anticoagulant action, reaches a level sufficient for expression of its pharmacological actions. Therefore, the compound of the present invention is useful as a therapeutic and/or prophylactic agent for diseases caused by thrombus formation.Type: GrantFiled: May 18, 2011Date of Patent: May 7, 2013Assignee: Eisai R&D Management Co., Ltd.Inventors: Richard Clark, Fumiyoshi Matsuura, Masanobu Shinoda, Shinsuke Hirota, Kazunobu Kira, Hiroshi Azuma, Atsushi Takemura, So Yasui, Kazutomi Kusano, Masaki Mikamoto, Takao Omae
-
Publication number: 20130053563Abstract: By oral administration of a compound represented by the following Formula (I): the blood level of Compound (IV): which has an excellent inhibitory action against blood coagulation factor VIIa and the anticoagulant action, reaches a level sufficient for expression of its pharmacological actions. Therefore, the compound of the present invention is useful as a therapeutic and/or prophylactic agent for diseases caused by thrombus formation.Type: ApplicationFiled: May 18, 2011Publication date: February 28, 2013Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Richard Clark, Fumiyoshi Matsuura, Masanobu Shinoda, Shinsuke Hirota, Kazunobu Kira, Hiroshi Azuma, Atsushi Takemura, So Yasui, Kazutomi Kusano, Masaki Mikamoto, Takao Omae
-
Patent number: 8163787Abstract: A compound represented by the following general formula (1) or salts thereof or hydrates of the foregoing: wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.; and Z1 and Z2 each independently represent hydrogen.Type: GrantFiled: January 13, 2011Date of Patent: April 24, 2012Assignee: Eisai R&D Management Co., Ltd.Inventors: Richard Clark, Fumiyoshi Matsuura, Kazunobu Kira, Shinsuke Hirota, Hiroshi Azuma, Tadashi Nagakura, Tatsuo Horizoe, Kimiyo Tabata, Kazutomi Kusano, Takao Omae, Atsushi Inoue
-
Publication number: 20110112109Abstract: A compound represented by the following general formula (1) or salts thereof or hydrates of the foregoing: wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.; and Z1 and Z2 each independently represent hydrogen.Type: ApplicationFiled: January 13, 2011Publication date: May 12, 2011Inventors: Richard CLARK, Fumiyoshi Matsuura, Kazunobu Kira, Shinsuke Hirota, Hiroshi Azuma, Tadashi Nagakura, Tatsuo Horizoe, Kimiyo Tabata, Kazutomi Kusano, Takao Omae, Atsushi Inoue
-
Patent number: 7928228Abstract: A Compound represented by the following general formula (1): wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.; and Z1 and Z2 each independently represent hydrogen or salts thereof or hydrates of the foregoing.Type: GrantFiled: March 29, 2010Date of Patent: April 19, 2011Assignees: Eisai Co., Ltd., Eisai R&D Management Co., Ltd.Inventors: Richard Clark, Fumiyoshi Matsuura, Kazunobu Kira, Shinsuke Hirota, Hiroshi Azuma, Tadashi Nagakura, Tatsuo Horizoe, Kimiyo Tabata, Kazutomi Kusano, Takao Omae, Atsushi Inoue
-
Patent number: 7816522Abstract: A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.Type: GrantFiled: March 22, 2007Date of Patent: October 19, 2010Assignee: Eisai Co., Ltd.Inventors: Richard Clark, Fumiyoshi Matsuura, Kazunobu Kira, Shinsuke Hirota, Hiroshi Azuma, Tadashi Nagakura, Tatsuo Horizoe, Kimiyo Tabata, Kazutomi Kusano, Takao Omae, Atsushi Inoue
